Building a brighter future with patient support programmes
In this issue, our cover article focuses on the importance of patient support programmes (PSPs) and how they are key to improving patient health.
As Danny Buckland writes in his article on page 30, PSPs are integral to therapy design and patient outcomes, and are the foundations that will make pharma’s new era function and thrive. They are the multipurpose building blocks that improve patient safety, pharmacovigilance, trial enrolment and retention, disease management, adherence, market share and quality of life for patients. They have proliferated in recent years and are becoming increasingly adept at tailoring content for individual patients to cope with complex regimens and engaging with diverse and hard-to-reach communities.
Turn to page 24 to read Rich Quelch’s article on the importance of future-proofing pharma
supply chains by improving inefficiencies in global health architecture. With the threat of more global pandemics in the future a certainty, not a question, these inefficiencies need to be addressed. Rich looks at the key lessons COVID-19 has taught us and how the international community can work together more closely to ensure future pandemic preparedness.
Despite being overshadowed by the pandemic, the fight against antimicrobial resistance continues., In this issue, Jonathan Cooke talks about how antibiotics that all but eradicated tuberculosis from Europe have lost their potency, leaving the world vulnerable to a disease that still infects 10 million people a year and is already the second leading infectious killer after COVID-19. Read more on page 16.
Looking ahead, our October issue will look UK market access. Market access is about getting the right treatment to the right patient at the right time, but enabling faster patient access to therapies remains a key challenge for pharma companies.
If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com
I hope you enjoy this issue!
